1-11 of 11
Mark R. Bray
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Inhibition of Threonine Tyrosine Kinase Suppressed TP53- mutated Acute Myeloid Leukaemia Via Synergism with Venetoclax and Activation of the Cgas-Sting Pathway

Wing Lam, Koon C. Chan, Kwui-Wa Tong, Ka-Lam Ng, Mark R Bray, Tak-Wah Mak, Cheuk-Him Man, Anskar Y. H. Leung
Journal: Blood
Blood (2024) 144 (Supplement 1): 1399.
https://doi.org/10.1182/blood-2024-201920
Published: 2024
Journal Articles

Preliminary Results from a Phase 1b/2 Open-Label, Multicenter, Dose Optimization Clinical Study of the Safety, Tolerability, and Pharmacokinetic (PK) and Pharmacodynamic (PD) Profiles of Cfi-400945 As a Single Agent or in Combination with Azacitidine in Patients (Pts) with Acute Myeloid Leukemia, Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia (TWT-202)

Brian A. Jonas, Karen Yee, Alice Mims, Paul B. Koller, Joseph Brandwein, Gail J. Roboz, Glenn Michelson, Linh Nguyen, Mark R Bray, Emily Roberts-Thomson, Roger Sidhu, Gautam Borthakur
Journal: Blood
Blood (2023) 142 (Supplement 1): 4294.
https://doi.org/10.1182/blood-2023-182027
Published: 2023
Journal Articles

Polyploidy Is Necessary for Apoptotic Cell Death in TP53 -Mut AML in Response to Polo-like-Kinase 4 (PLK4) Inhibition and Results in Caspase 3 Cleavage

Edward Ayoub, Akhil Marupudi, Yuki Nishida, Rafael Heinz Montoya, Vakul Mohanty, Wencke Walter, Mark R Bray, Tallie Patsilevas, Steffen Boettcher, Ghayas C. Issa, Ken Chen, Torsten Haferlach, Gautam Borthakur, Michael Andreeff
Journal: Blood
Blood (2022) 140 (Supplement 1): 5941–5943.
https://doi.org/10.1182/blood-2022-170152
Published: 2022
Journal Articles

Preliminary Results from a Phase 2 Open-Label, Multicenter, Dose Optimization Clinical Study of the Safety, Tolerability, and Pharmacokinetic (PK) and Pharmacodynamic (PD) Profiles of Cfi-400945 As a Single Agent or in Combination with Azacitidine or Decitabine in Patients with Acute Myeloid Leukemia, Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia (TWT-202)

Brian A. Jonas, Karen Yee, Paul B. Koller, Joseph Brandwein, Alice S. Mims, Glenn C. Michelson, Linh Nguyen, Mark R Bray, Emily L Roberts-Thomson, Gautam Borthakur
Journal: Blood
Blood (2022) 140 (Supplement 1): 9076–9077.
https://doi.org/10.1182/blood-2022-158370
Published: 2022
Journal Articles

A Phase 2 Open-Label, Multicenter, Dose Optimization Clinical Study of the Safety, Tolerability, and Pharmacokinetic (PK) and Pharmacodynamic (PD) Profiles of Cfi-400945 As a Single Agent or in Combination with Azacitidine or Decitabine in Patients with Acute Myeloid Leukemia, Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia (TWT-202)

Gautam Borthakur, Brian A. Jonas, Emily L Roberts-Thomson, Glenn C. Michelson, Mark R Bray
Journal: Blood
Blood (2021) 138 (Supplement 1): 4432.
https://doi.org/10.1182/blood-2021-148808
Published: 2021
Journal Articles

A Phase 2 Open-Label, Multicenter, Dose Optimization Clinical Study of the Safety, Tolerability, and Pharmacokinetic (PK) and Pharmacodynamic (PD) Profiles of Cfi-400945 As a Single Agent or in Combination with Azacitidine or Decitabine in Patients with Acute Myeloid Leukemia

Brian A Jonas, MD PhD, Dale L. Bixby, MD, Joseph M Brandwein, MD, Karen W.L. Yee, MD, Tracy Murphy, MDFRCP,FRCPath, Mark D. Minden, Glenn C. Michelson, MD, Mark R Bray, Emily Elizabeth Roberts-Thomson, Gautam Borthakur, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 24–25.
https://doi.org/10.1182/blood-2020-136004
Published: 2020
Journal Articles

Preliminary Results from a Phase 1 Study of Cfi-400495, a PLK4 Inhibitor, in Patients with Acute Myeloid Leukemia and High Risk MDS

Tracy Murphy, MDFRCP,FRCPath, Brian Leber, MD, Mark R Bray, Steven M Chan, MD PhD, Vikas Gupta, MD FRCP, FRCPath, Dina Khalaf, BSc, MSc, MD, Dawn Maze, MDFRCPC,MSc, Caroline J McNamara, MBBS, Aaron D Schimmer, MD PhD, Andre C. Schuh, Hassan Sibai, MBBS, Graham Fletcher, Debbie Valiquette, Kylie Martin, BSc, RN, BSN, Mark D. Minden, Karen W.L. Yee, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 1–2.
https://doi.org/10.1182/blood-2020-138822
Published: 2020
Journal Articles

The Novel Aurora Kinase Inhibitor ENMD-2076 Has Potent Single Agent Activity against Multiple Myeloma (MM) in Vitro and in Vivo , and Shows Synergistic Activity in Combination with Lenalidomide

Xiaojing Wang, PhD, Anthony L. Sinn, Attaya Suvannasankha, MD, Colin D. Crean, Li Chen, MD, Shuhong Zhang, PhD, Jing Liang, MD, Genglin Zhang, Karen E. Pollok, PhD, Rafat Abonour, MD, Carolyn Sidor, MD, Mark R. Bray, PhD, Sherif S. Farag, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 3660.
https://doi.org/10.1182/blood.V112.11.3660.3660
Published: 2008
Journal Articles

Inhibition of Multiple Myeloma Tumor Growth and FGFR3 by the Aurora-Angiogenesis Inhibitor ENMD-981693.

Todd A. Hembrough, Xiaoru Chen, Patricia A. Burke, Glenn M. Swartz, Kathleen Bengali, Richard Brokx, Theresa M. LaVallee, Mark R. Bray
Journal: Blood
Blood (2007) 110 (11): 1209.
https://doi.org/10.1182/blood.V110.11.1209.1209
Published: 2007
Journal Articles

ENMD-981693 Is an Orally-Active Kinase Inhibitor with Activity towards Human Hematologic Cancers In Vitro and In Vivo .

Mark R. Bray, PhD, Graham C. Fletcher, PhD, Trisha A. Denny, John Xu, PhD, Xiaoru Chen, Patricia A. Burke, PhD, Wanda Franklin, Theresa M. LaVallee, PhD, Mark D. Minden, MD, PhD, Carolyn F. Sidor, MD, MBA
Journal: Blood
Blood (2006) 108 (11): 1377.
https://doi.org/10.1182/blood.V108.11.1377.1377
Published: 2006
Journal Articles

MKC-1 Is a Novel Agent That Induces Cell Cycle Arrest and Disrupts Multiple Survival Pathways in Hematologic Cancers.

Trisha A. Denny, Xiaoru Chen, Cassandra L. Waters, Patricia A. Burke, PhD, Graham C. Fletcher, PhD, John Xu, PhD, Carolyn F. Sidor, MD, MBA, Mark D. Minden, MD, PhD, Theresa M. LaVallee, PhD, Mark R. Bray, PhD
Journal: Blood
Blood (2006) 108 (11): 4390.
https://doi.org/10.1182/blood.V108.11.4390.4390
Published: 2006